Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Belci, Paola; Collo, Alessandro; Martorana, Maria Cristina; Evangelista, Andrea; Giunti, Sara; Gambino, Roberto; Cassader, Maurizio; Bo, Simona; Durazzo, Marilena

doi:10.20517/2394-5079.2015.53

Cited by 8 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the treatment-experienced were treated with IFN-based regimens, to which, in the under-50 age group, men also responded worse than women, so a higher percentage of them required antiviral retherapy. 50 In our analysis, women of childbearing age were significantly less burdened by comorbidities than men (40% vs. 44%) and were significantly less likely to require comedications (37% vs. 45%). In this regard, it is difficult for us to compare our results with other studies because, to the best of our knowledge, no research comparing patients at age below 50 years treated for HCV by sex has yet been published, while data on the population prevalence of comorbidities in this age group are disparate.…”

Section: Ta B L Ementioning

confidence: 64%

“…Another difference between the treated patient populations recognised in our analysis was the significantly higher proportion of men with a history of previous therapy failure compared to women. Most of the treatment‐experienced were treated with IFN‐based regimens, to which, in the under‐50 age group, men also responded worse than women, so a higher percentage of them required antiviral retherapy 50 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Dobrowolska,

Pawłowska,

Zarębska‐Michaluk

et al. 2024

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Eliminating hepatitis C virus (HCV) infection in the population of women of reproductive age is important not only for the health of women themselves but also for the health of newborns. This study aimed to evaluate the implementation of this goal by analysing the effectiveness of contemporary therapy in a large cohort from everyday clinical practice along with identifying factors reducing therapeutic success. The analysed population consisted of 7861 patients, including 3388 women aged 15–49, treated in 2015–2022 in 26 hepatology centres. Data were collected retrospectively using a nationwide EpiTer‐2 database. Females were significantly less often infected with HCV genotype 3 compared to males (11.2% vs. 15.7%) and less frequently showed comorbidities (40.5% vs. 44.2%) and comedications (37.2% vs. 45.2%). Hepatocellular carcinoma, liver transplantation, HIV and HBV coinfections were reported significantly less frequently in women. Regardless of the treatment type, females significantly more often reached sustained virologic response (98.8%) compared to males (96.8%). Regardless of gender, genotype 3 and cirrhosis were independent factors increasing the risk of treatment failure. Women more commonly reported adverse events, but death occurred significantly more frequently in men (0.3% vs. 0.1%), usually related to underlying advanced liver disease. We have demonstrated excellent effectiveness and safety profiles for treating HCV infection in women. This gives hope for the micro‐elimination of HCV infections in women, translating into a reduced risk of severe disease in both women and their children.

show abstract

Section: Ta B L Ementioning

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Dobrowolska,

Pawłowska,

Zarębska‐Michaluk

et al. 2024

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In terms of viral clearance, the number of studies in the past showed age and gender disparity after Interferon therapy. In one study by Belci et al [15], there was a significantly higher SVR in females aged ˂50 years. Likewise, Bhattacharya et al found a higher SVR in premenopausal women [16].…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience

Butt

Akbar

Abbasi

et al. 2019

Cureus

View full text Add to dashboard Cite

Introduction Hepatitis C virus (HCV) is the leading cause of cirrhosis. The advent of Directly Acting Antivirals (DAAs) like Sofosbuvir (SOF) has dramatized the treatment and is the cornerstone for the treatment of HCV. Most trials have been conducted in HCV genotype 1 (GT-1) and data for Interferon-free regimen in genotype 3 (GT-3) is limited especially in cirrhotic patients. Aim To evaluate the safety and efficacy of SOF plus Ribavirin® (RIB) in patients with compensated and decompensated cirrhosis. Methods This was a quasi-experimental study in HCV patients with compensated and decompensated cirrhosis. Each group (compensated and decompensated) was further subdivided into the treatment-naïve and treatment-experienced groups. Efficacy was assessed by end treatment response (ETR) and sustained viral response (SVR) in the treatment-naïve and experienced groups. Adverse events were recorded on designed proforma on serial follow-up visits. Results The study consisted of 110 consecutive patients. Among 110 patients, 51 had compensated cirrhosis and 59 had decompensated cirrhosis. The mean age was 53.8 ± 11 years. Males were n=56 (50.9%) and females were n=54 (49.1%). All the patients in Child-Turcotte-Pugh class A were in the compensated group. CTP B class was found to be 10.5% and 89.5% in the compensated and decompensated groups, respectively, whereas all the patients in CTP class C were in the decompensated group. In the compensated cirrhosis group, ETR was achieved in 36 (87.8%) treatment-naïve and 8 (88.9%) experienced patients. In decompensated cirrhosis, treatment-naïve and experienced patients achieved ETR in 28 (82.4%) and 18 (85.7%) patients, respectively. Whereas in compensated cirrhosis treatment-naïve and experienced patients, SVR was achieved in 25 (83.3%) and five (71.4%), respectively. In decompensated cirrhosis, 21 (77.8%) treatment-naïve and 12 (75%) experienced patients achieved SVR. The most common adverse events experienced by the patients were fatigue followed by myalgia, nausea, and diarrhea. The new onset of complications found due to cirrhosis were ascites, followed by hepatoma, upper gastrointestinal bleed, portosystemic encephalopathy, acute on chronic liver failure, and death. Conclusion Sofosbuvir in combination with Ribavirin® is safe but suboptimal in treatment outcomes, particularly in treatment-experienced patients with decompensated cirrhosis than in treatment-naive patients with compensated cirrhosis due to HCV GT-3.

show abstract

“…So in this study similar results were found. 41,42 There were 13 patients who discontinued the therapy. Discontinuation of therapy was mainly due to either side effects of the drugs or any other co-morbidity that imposed additional stress on the patient and led to inability to tolerate the therapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of sofosbuvir in interferon treated patients of hepatitis C infected with 3a genotype.

Zahoor¹,

Zahoor²,

Hameed³

et al. 2019

TPMJ

View full text Add to dashboard Cite

Objectives: Hepatitis C is a blood borne infection primarily disrupting the functional and architectural integrity of liver and has a considerable share in worldwide mortality and morbidity. Treatment strategies against the causative RNA-based virus has widely evolved over time with newer Direct Acting Antivirals (DAA) being recently introduced. This study serves to assess the efficacy of Sofosbuvir (DAA) in patients of HCV genotype 3a with prior treatment with interferon. Study Design: An Open label, Prospective Quasi Experimental Study. Setting: Mayo Hospital, Lahore. Period: September 2016 to December 2017. Material and Methods: 212 patients with genotype 3a who had been previously treated with interferon (INF). They were treated with Sofosbuvir 400mg once daily and Ribavirin 400mg thrice daily. The treatment duration was 24 weeks following which the end of treatment response (ETR) was determined by quantifying viral load by Polymerase Chain Reaction (PCR). Results: Of the 212 patients enrolled, 50 patients did not give follow up either due to availability issues or due to non-compliance. 13 patients left the treatment due to comorbidities. 149 patients completed the treatment out of whom 131 patients showed positive response (87.9%). Nine patients with high viral load showed relapse while nine patients were non-responders. Conclusion: In interferon experienced patients of HCV genotype 3a, Sofosbuvir has shown to reach sublimecure rates which may serve to obviate conventional treatment strategies owing to their longer treatment duration and significant adverse effects. As demonstrated by this study, the modest safety profile coupled with an enhanced therapeutic efficacy of Sofosbuvir is expected to revolutionize treatment strategies against Hepatitis C limiting the spread and hence the incidence of disease.

show abstract

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Cited by 8 publications

References 25 publications

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience

Efficacy of sofosbuvir in interferon treated patients of hepatitis C infected with 3a genotype.

Contact Info

Product

Resources

About